NASDAQ:CDXSCodexis Stock Price, Forecast & News

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDXS shares have increased by 35.9% and is now trading at $13.75.
View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Codexis.

Codexis is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. The biotechnology company had revenue of $14.67 million for the quarter, compared to the consensus estimate of $12.53 million. Codexis had a negative net margin of 21.40% and a negative return on equity of 14.24%.
View Codexis' earnings history.

3 brokerages have issued 1 year target prices for Codexis' shares. Their forecasts range from $16.00 to $21.00. On average, they anticipate Codexis' stock price to reach $18.50 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Codexis.

Press coverage about CDXS stock has trended extremely negative on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Codexis earned a news sentiment score of -4.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Codexis.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Canopy Growth (CGC), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), Crispr Therapeutics (CRSP), Micron Technology (MU), Alibaba Group (BABA), Catalyst Pharmaceuticals (CPRX) and Enphase Energy (ENPH).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (1.36%), Assenagon Asset Management S.A. (1.00%), Ziegler Capital Management LLC (0.77%), Essex Investment Management Co. LLC (0.52%), Taylor Frigon Capital Management LLC (0.38%) and Swiss National Bank (0.21%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Kathleen Sereda Glaub, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., New York State Common Retirement Fund, Ingalls & Snyder LLC, Essex Investment Management Co. LLC, Ziegler Capital Management LLC, UBS Group AG, and Envestnet Asset Management Inc.. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, and Thomas R Baruch.
View insider buying and selling activity for Codexis.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC, Conestoga Capital Advisors LLC, Assenagon Asset Management S.A., First Trust Advisors LP, Trexquant Investment LP, Swiss National Bank, Exchange Traded Concepts LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $13.75.

Codexis has a market capitalization of $811.53 million and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Codexis employs 132 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]